Role of TNF/TNFR in autoimmunity: Specific TNF receptor blockade may be advantageous to anti-TNF treatments

Cytokine and Growth Factor Reviews

Volumn 13, Issue 4-5, 2002, Pages 315-321

  Kollias, George ^a   Kontoyiannis, Dimitris ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Autoimmunity; Pathophysiology; Transmembrane

Indexed keywords

DOUBLE STRANDED DNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHRONIC INFLAMMATION; DISEASE COURSE; DISEASE MODEL; ENTERITIS; INFLAMMATION; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; RECEPTOR BLOCKING; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ANIMALS; ANTIGENS, CD; APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL DIFFERENTIATION; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED MRL LPR; MICE, INBRED NOD; MICE, INBRED NZB; MICE, TRANSGENIC; MYELIN SHEATH; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 0036694562     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(02)00019-9     Document Type: Review

References (74)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8.
3. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
4. Rudin W, Eugster HP, Bordmann G, et al. Resistance to cerebral malaria in tumor necrosis factor-alpha/beta-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am J Pathol 1997;150:257-66.
5. Zhan Y, Cheers C. Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors. J Immunol 1998;161:1447-53.
6. Higuchi Y, Herrera P, Muniesa P, et al. Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 1992;176:1719-31.
7. Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha and TNF-beta transgenic mice. J Immunol 1993;150:4136-50.
8. Probert L, Keffer J, Corbella P, et al. Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immunol 1993;151:1894-906.
9. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
10. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 1995;92:11294-8.
11. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997;158:438-45.
12. Akassoglou K, Bauer J, Kassiotis G, et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998;153:801-13.
13. Kontoyiannis D, Pasparakis M, Pizarro T, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut associated immunopathologies. Immunity 1999;10:387-98.
14. + T cells to cause immunopathology. J Exp Med 1998;187:763-74.
15. Satoh J, Seino H, Abo T, et al. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989;84:1345-8.
16. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
17. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CAJ, Flavell RA. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184:1963-74.
18. Cope A, Ettinger R, McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997;148:307-12.
19. Green EA, Eynon EE, Flavell RA. Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998;9:733-43.
20. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999;169:175-94.
21. Kontoyiannis D, Kollias G. Fibroblast biology. Synovial fibroblasts in rheumatoid arthritis: leading role or chorus line? Arthritis Res 2000;2:342-3.
22. Piguet PF, Vesin C, Guo J, Donati Y, Barazzone C. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol 1998;28:3499-505.
23. Benoist C, Mathis D. Cell death mediators in autoimmune diabetes: no shortage of suspects. Cell 1997;89:1-3.
24. Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987;139:2593-7.
25. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-46.
26. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;184:1397-411.
27. Le Hir M, Bluethmann H, Kosco-Vilbois MH, et al. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med 1996;183:2367-72.
28. Kassiotis G, Kranidioti K, Kollias G. Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness. J Neuroimmunol 2001;119:239-47.
29. Ranges GE, Zlotnik A, Espevik T, Dinarello CA, Cerami A, Palladino MAJ. Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med 1988;167:1472-8.
30. Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 1993;151:4637-41.
31. Lahn M, Kalataradi H, Mittelstadt P, et al. Early preferential stimulation of gamma delta T cells by TNF-alpha. J Immunol 1998;160:5221-30.
32. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
33. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-84.
34. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-51.
35. Speiser DE, Sebzda E, Ohteki T, et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 1996;26:3055-60.
36. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998;395:189-94.
37. Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel RP. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 1999;189:1033-42.
38. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-7.
39. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001;193:427-34.
40. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
41. Anonymous TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53:457-65.
42. Jacob CO, Hwang F, Lewis GD, Stall AM. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine 1991;3:551-61.
43. Jacob CO, Lee SK, Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996;156:3043-50.
44. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol 1990;144:1753-8.
45. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989;143:3470-5.
46. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
47. Fujimura T, Hirose S, Jiang Y, et al. Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int Immunol 1998;10:1467-72.
48. Rahman ZS, Tin SK, Buenaventura PN, et al. A novel susceptibility locus on chromosome 2 in the (New Zealand Black x New Zealand White)F1 hybrid mouse model of systemic lupus erythematosus. J Immunol 2002;168:3042-9.
49. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000;30:2038-47.
50. Ghatak S, Sainis K, Owen FL, Datta SK. T-cell-receptor beta- and I-A beta-chain genes of normal SWR mice are linked with the development of lupus nephritis in NZB x SWR crosses. Proc Natl Acad Sci USA 1987;84:6850-3.
51. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994;1:219-29.
52. Le Hir M, Haas C, Marino M, Ryffel B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest 1998;78:1625-31.
53. Ryffel B, Eugster H, Haas C, Le Hir M. Failure to induce anti-glomerular basement membrane glomerulonephritis in TNF alpha/beta deficient mice. Int J Exp Pathol 1998;79:453-60.
54. Hirahashi J, Takayanagi A, Hishikawa K, et al. Overexpression of truncated I kappa B alpha potentiates TNF-alpha-induced apoptosis in mesangial cells. Kidney Int 2000;57:959-68.
55. Duffield JS, Erwig LP, Wei X, Liew FY, Rees AJ, Savill JS. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J Immunol 2000;164:2110-9.
56. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. Lupus 2001;10:23-31.
57. Zhou T, Edwards CK, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996;156:2661-5.
58. Korner H, Cretney E, Wilhelm P, et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld). J Exp Med 2000;191:89-96.
59. Haridas V, Darnay BG, Natarajan K, Heller R, Aggarwal BB. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 1998;160:3152-62.
60. Douni E, Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNFR) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNFR. J Exp Med 1998;188:1343-52.
61. Morita C, Horiuchi T, Tsukamoto H, et al. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001;44:2819-27.
62. Cawley D, Chiang BL, Naiki M, Ansari AA, Gershwin ME. Comparison of the requirements for cognate T cell help for IgG anti-double-stranded DNA antibody production in vitro: T helper-derived lymphokines replace T cell cloned lines for B cells from NZB.H-2bm12 but not B6.H-2bm12 mice. J Immunol 1993;150:2467-77.
63. McSorley SJ, Soldera S, Malherbe L, et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFalpha by islet beta cells. Immunity 1997;7:401-9.
64. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-66.
65. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-51.
66. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous Clq deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-9.
67. Paul E, Carroll MC. SAP-less chromatin triggers systemic lupus erythematosus. Nat Med 1999;5:607-8.
68. Bopst M, Haas C, Car B, Eugster HP. The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin. Eur J Immunol 1998;28:4130-7.
69. Wallgren A, Festin R, Gidlof C, Dohlsten M, Kalland T, Totterman TH. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 1993;82:1230-8.
70. Lens SM, Tesselaar K, den Drijver BF, van Oers MH, van Lier RA. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol 1996;156:507-14.
71. Rolink AG, Melchers F. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr Opin Immunol 2002;14:266-75.
72. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
73. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
74. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.